期刊文献+

2型糖尿病病程进展与胰岛素强化治疗 被引量:72

Relationship of type 2 diabetes mellitus progression and intensive insulin therapy
原文传递
导出
摘要 T2DM是一种进展性疾病,患者胰岛β细胞功能的不断下降导致血糖逐渐恶化,而改善胰岛β细胞功能的干预措施则可延缓高血糖进展。胰岛素强化治疗能更好地保护胰岛β细胞功能、改善血糖控制,因此,在T2DM病程的各个阶段对患者进行胰岛素强化治疗均具有显著的临床获益。在实现胰岛素强化治疗过程中,餐后血糖(PPG)的管理尤为重要,基础—餐时胰岛素方案精细灵活,可以满足患者不断进展的治疗需求。胰岛素类似物能更好地模拟生理性胰岛素分泌,以门冬胰岛素为代表的速效胰岛素类似物和基础胰岛素联合使用或应用于持续皮下胰岛素输注(CSII)中,其作为强化治疗方案的有效性和安全性已得到一系列研究证据的支持。 Type 2 diabetes mellitus(T2DM) is a progressive disease.Declining islet β cell function leads to the worsening of hyperglycaemia.Therefore,interventions to protect β cell function will slow down the progression of hyperglycaemia.Intensive insulin therapy can effectively control the blood glucose at all stages of T2 DM.During the course of intensive insulin therapy,it is particularly important for T2 DM patients to control postprandial blood glucose(PPG).Basal-bolus insulin regimen,which is accurate and flexible,taking into account both fasting glucose and PPG,can meet different demands during treatments.The efficacy and safety of short-acting insulin analogues such as insulin aspart,used in combination with basal insulin or in continuous subcutaneous insulin infusion(CSII) regimen to mimic human insulin secretion are well documented.
作者 李延兵
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2016年第3期286-288,共3页 Chinese Journal of Diabetes
关键词 糖尿病 2型 胰岛素强化治疗 胰岛素类似物 Diabetes mellitus type 2 Intensive insulin therapy Insulin analogues
  • 引文网络
  • 相关文献

参考文献21

  • 1Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20: 1353-1356.
  • 2Li Y,Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care, 2004, 27:2597-2602.
  • 3Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel- group trial. Lancet, 2008,371 : 1753-1760.
  • 4Kramer CK, Zinman B, Retnakaran R. Short term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2013,1: 28-34.
  • 5Liu J, Liu J, Fang D, et al. Fasting plasma glucose after intensive insulin therapy predicted long term glycemic control in newly diagnosed type 2 diabetic patients. Endocr J, 2013,60 : 725-732.
  • 6Chen A, Huang Z, Wan X, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care, 2012, 35: 474-481.
  • 7Huang Z, Wan X, Liu J, et al. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant a lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther,2013,15:859-869.
  • 8Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous- subcutaneous insulin infusion therapy. Diabetes Metab Res Rev, 2003,19 : 124-130.
  • 9Shichiri M,Kishikawa H,Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 2000,23 (Suppl 2) : B21-B29.
  • 10Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 2003,26: 881-885.

二级参考文献16

  • 1Li YB, Xu W, Liao ZH, et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function.Diabetes Care, 2004, 27:2597-2602.
  • 2.
  • 3Brange J, Owens DR, Kang S, et al.Monomeric insulins and their experimental and clinical implications.Diabetes Care, 1990, 13:923-954.
  • 4Home PD, Barriocanal L, Lindholm A, et al.Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in health volunteers.Eur J Clin Pharmacol, 1999, 55:199-203.
  • 5Heinemann L, Kapitza C, Starke A, et al.Time-action profile of the insulin analogue B28 Asp.Diabet Med, 1996, 13:683-684.
  • 6.
  • 7Bode BW, Strange P.Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.Diabetes Care, 2001, 24:69-72.
  • 8Umpierrez GE,Hellman R,Korytkowski MT. Management of hyperglycemia in hospitalized patients in non-critical care setting:an endocrine society clinical practice guideline[J].{H}Journal of Clinical Endocrinology and Metabolism,2012.16-38.
  • 9Pan C,Yang W,Jia W. Management of Chinese patients with type 2 diabetes,1998-2006:the Diabcare-China surveys[J].{H}CURRENT MEDICAL RESEARCH AND OPINION,2009.39-45.
  • 10Leahy JL. Basal prandial insulin therapy:Scientific concept review and application[J].{H}AMERICAN Journal OF THE MEDICAL SCIENCES,2006.24-31.

共引文献6817

同被引文献582

引证文献72

;
使用帮助 返回顶部